Aevi Genomic Medicine, Inc. reported consolidated unaudited earnings results for the third quarter and nine months ended September 30, 2017. For the quarter, the company reported a net loss of $8.61 million or $0.23 per share, compared with a net loss of $10.57 million or $0.29 per share for the comparative quarter in 2016. Operating loss was $8.569 million against $10.571 million a year ago. Loss before taxes was $8.605 million against $10.557 million a year ago. For the nine months, the company reported a net loss of $27.555 million or $0.74 diluted per share, compared with a net loss of $33.421 million or $0.97 diluted per share a year ago. Operating loss was $27.540 million against $33.399 million a year ago. Loss before taxes was $27.555 million against $33.405 million a year ago.